When the company raises the curtain and reveals the second recall of their loaned shares, this one announced with either CMML approval, or news from Novavax, or a covid EUA, there will be an even greater response in share price than we saw previously. So I will re-enter my four highest-priced sells at $100, $150, $200, and $250 (as I indicated before), and I will try not to sell my other shares too cheaply. I have no doubt the Q's will be submitted, once the delay of the financial reports has served its purpose.